Michal Florczyk
Overview
Explore the profile of Michal Florczyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kurzyna P, Witowicz A, Kedzierski P, Florczyk M, Banaszkiewicz M, Szwed P, et al.
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941569
Several studies describe the sex-specific differences in cardiovascular diseases. However, there is still limited research reporting the difference between men and women with chronic thromboembolic pulmonary hypertension (CTEPH) treated with...
2.
Kedzierski P, Banaszkiewicz M, Florczyk M, Pilka M, Manczak R, Wieteska-Milek M, et al.
Biomedicines
. 2025 Jan;
13(1.
PMID: 39857754
: Treprostinil, which is administered via continuous subcutaneous or intravenous infusion, is a medication applied in the treatment of pulmonary arterial hypertension (PAH). The dose of treprostinil is adjusted on...
3.
Banaszkiewicz M, Pietrasik A, Darocha S, Pilka M, Florczyk M, Dobosiewicz A, et al.
Arch Med Sci
. 2024 Dec;
20(5):1442-1451.
PMID: 39649252
Introduction: Non-invasive tests that may improve clinical evaluation of pulmonary hypertension (PH) are needed. The purpose of this study was to assess the role of soluble ST2 (sST2) in patients...
4.
Waligora M, Kurzyna M, Mularek-Kubzdela T, Skoczylas I, Chrzanowski L, Blaszczak P, et al.
Chest
. 2024 Nov;
PMID: 39528108
Background: Current guidelines do not recommend β-blockers in pulmonary arterial hypertension (PAH) unless indicated by comorbidities. However, the evidence regarding the role of β-blockers in PAH is contradictory. Research Question:...
5.
Wieteska-Milek M, Zielinski P, Florczyk M, Szmit S, Rajewska B, Kurzyna M
Cardiovasc Diagn Ther
. 2024 Nov;
14(5):810-820.
PMID: 39513137
Background: Appropriate levels of physical activity (PhA) provide health benefits to patients with chronic diseases, including patients with pulmonary arterial hypertension (PAH). In this study, we examined the effect of...
6.
Wieteska-Milek M, Witowicz A, Szmit S, Florczyk M, Peller M, Dzienisiewicz M, et al.
J Clin Med
. 2024 Jun;
13(12).
PMID: 38930062
There was increased risk of mental disturbances during the COVID-19 pandemic. Patients with chronic diseases, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), were particularly vulnerable. Our...
7.
Kurzyna P, Banaszkiewicz M, Florczyk M, Kepski J, Pilka M, Kedzierski P, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672644
The risk of venous thromboembolism (VTE) in the oncology population is significantly higher than in non-cancer patients. Inferior vena cava (IVC) filters may, therefore, be an important part of VTE...
8.
Pilka M, Darocha S, Florczyk M, Manczak R, Banaszkiewicz M, Kedzierski P, et al.
J Clin Med
. 2023 Dec;
12(24).
PMID: 38137690
Background: The ECG-PH index (PH-ECG score) has been proposed as a valuable ECG-derived method of evaluating the effectiveness of balloon pulmonary angioplasty (BPA) in chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary...
9.
Banaszkiewicz M, Kurzyna P, Kubikowska N, Mucha M, Rudnik A, Gasecka A, et al.
J Clin Med
. 2023 Aug;
12(16).
PMID: 37629379
In this article, we discuss the topic of chronic thromboembolic pulmonary disease (CTEPD) and the growing role of balloon pulmonary angioplasty (BPA) in its treatment. We present the pathophysiology of...
10.
Wieteska-Milek M, Kusmierczyk-Droszcz B, Betkier-Lipinska K, Szmit S, Florczyk M, Zielinski P, et al.
Pulm Circ
. 2023 Jun;
13(2):e12244.
PMID: 37266140
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients have a more severe COVID-19 course than the general population. Many patients report different persistent symptoms after SARS-CoV-2 infection....